文献速递类风湿关节炎其他结缔组织病

类风湿关节炎患者间质性肺病的患者层面预测因素:一项系统综述

Patient-level factors predictive of interstitial lung disease in rheumatoid arthritis: a systematic review.
PubMed 文献 · RMD Open · 2023-01-01

该研究通过系统文献综述评估了在间质性肺病(ILD)发生前可评估的患者层面因素,发现年龄、性别、吸烟状态和自身抗体与类风湿关节炎(RA)患者发生ILD存在一致性关联,而克氏纤毛素6等生物标志物无符合标准的研究。作者认为这些发现为开发风险算法以筛选RA患者中ILD候选者提供了初步基础。

要点

  • 年龄、性别、吸烟状态和自身抗体与RA患者发生ILD存在一致性关联。
  • 克氏纤毛素6等生物标志物无符合本系统综述纳入标准的研究。
  • 作者认为这些发现为未来开发RA患者ILD风险算法提供了初步基础。

核心结论

  • 该分析为识别患者层面因素以开发潜在风险算法、筛选可能为ILD候选者的RA患者提供了初步步骤。
  • 研究结果为未来研究提供了有益基础,以改善对RA患者疾病过程的理解及对ILD发生和进展风险患者的照护。

研究设计与样本

  • 系统文献综述,检索PubMed、Embase和Scopus截至2021年7月的10年期间文献。
  • 纳入报告RA患者伴或不伴ILD的患者层面因素、且在ILD发生前评估(或随时间不变因而可外推至ILD发生前)的文献进行证据评估。
  • MUC5B遗传变异和甲氨蝶呤治疗因已被广泛研究其与ILD的关联而未纳入证据评估。

主要发现

  • 发现年龄、性别、吸烟状态和自身抗体与ILD发生存在一致性关联。
  • 对于克氏纤毛素6等已被证明对ILD有诊断价值的生物标志物,没有符合本研究标准的研究发表。

关键数值与推荐

  • 系统综述检索时间范围为截至2021年7月的10年期间。
  • 纳入标准为报告RA患者伴或不伴ILD的患者层面因素、且在ILD发生前评估(或随时间不变可外推至ILD发生前)的文献。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • MUC5B遗传变异和甲氨蝶呤治疗因已被广泛研究而未纳入证据评估。
  • MUC5B遗传变异和甲氨蝶呤治疗未纳入本系统综述的证据评估。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Objective Interstitial lung disease (ILD) is an important cause of mortality in some patients with rheumatoid arthritis (RA). Patient-level factors may predict which patients with RA are at the highest risk of developing ILD and are therefore candidates for screening for this complication of the underlying disease.Methods A systematic literature review was performed using PubMed, Embase and Scopus over a 10-year period up to July 2021. Publications reporting patient-level factors in patients with RA with and without ILD that were assessed before development of ILD (or were unchanged over time and therefore could be extrapolated to before development of ILD) were retrieved for assessment of evidence. Genetic variation in MUC5B and treatment with methotrexate were not included in the assessment of evidence because these factors have already been widely investigated for association with ILD.Results We found consistent associations of age, sex, smoking status and autoantibodies with development of ILD. For biomarkers such as Krebs von den Lungen 6, which have been shown to be diagnostic for ILD, there were no publications meeting criteria for this study.Conclusions This analysis provides an initial step in the identification of patient-level factors for potential development of a risk algorithm to identify patients with RA who may be candidates for screening for ILD. The findings represent a useful basis for future research leading to an improved understanding of the disease course and improved care for patients with RA at risk of development and progression of ILD.

来源:RMD Open,查看原文。版权归原作者所有。

引用

  1. Matteson EL, Matucci-Cerinic M, Kreuter M, et al. Patient-level factors predictive of interstitial lung disease in rheumatoid arthritis: a systematic review. RMD Open. 2023. PMID: 37507209. doi:10.1136/rmdopen-2023-003059

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。